Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company whose news flow centers on its NMDA-based drug pipeline and interventional psychiatry operations. Company announcements frequently highlight progress with NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral D-cycloserine/lurasidone combination, both aimed at serious central nervous system disorders such as suicidal depression and suicidal bipolar depression.
Investors following NRXP news can expect updates on FDA interactions, including Fast Track and Breakthrough Therapy designations, Abbreviated New Drug Application (ANDA) milestones for preservative-free ketamine, and New Drug Application (NDA) activities. The company also reports on the use of large Real World Evidence datasets to support potential Accelerated Approval pathways for NRX-100 in suicidal ideation associated with depression and bipolar depression.
Another recurring theme in NRx Pharmaceuticals’ news is the expansion of its HOPE Therapeutics subsidiary, which operates interventional psychiatry clinics. Releases describe clinic acquisitions, strategic interests in practices, and deployment of treatments such as ketamine-based therapies, Transcranial Magnetic Stimulation (TMS), Hyperbaric Oxygen Therapy, and digital therapeutics for suicidal depression, PTSD, and related conditions. Updates often cover new treatment protocols that combine TMS with D-cycloserine and other medications.
NRXP news items also include corporate developments such as conference presentations, corporate update calls, financing transactions, and changes in independent registered public accounting firms, as reflected in SEC filings. For investors and observers, the news stream provides ongoing insight into NRx Pharmaceuticals’ clinical progress, regulatory steps, clinic network growth, and capital markets activity related to its focus on Neuroplastic Therapies and suicidal depression.
Hope Therapeutics (Nasdaq: NRXP) announced a strategic partnership with Emobot to deploy its AI-powered Depression Thermometer across Hope’s interventional psychiatry clinics, integrating passive smartphone monitoring of facial expressions, vocal tone, and actigraphy to detect early relapse in TRD.
Preliminary pooled validation across three prospective studies showed concordance with MADRS (r=0.89) and PHQ-9 (r=0.83); Hope expects the tool to enable timely "recapture" interventions and improve patient outcomes.
NRx Pharmaceuticals (Nasdaq: NRXP) reported full-year 2025 results and operational progress including $7.8 million cash at year-end, conversion of all previously issued convertible debt to common stock, and reduced loss from operations to $16.2 million. The company cited a favorable FDA bioequivalence signal for preservative-free ketamine and anticipates at least one ANDA approval in Q3 2026.
NRx also reported first clinic revenue from five HOPE Therapeutics sites, a nationwide partnership with neurocare AG for TMS clinics, a Type C FDA meeting on NRX-100, and filing of an IND for NRX-101.
NRx Pharmaceuticals (Nasdaq: NRXP) will report full year 2025 financial results and provide a corporate update on March 24, 2026. The company will host a conference call at 8:00am ET covering FY2025 results and progress across its drug development programs and the HOPE Therapeutics clinical network.
A live webcast will be available on the company's investor site and telephone dial-ins are provided for domestic and international participants.
NRx Pharmaceuticals (Nasdaq: NRXP) said the FDA Office of Generic Drugs told the company it has not identified bioequivalence deficiencies for NRx’s preservative-free ketamine ANDA; the communication is preliminary pending final supervisory review. NRx expects an FDA GDUFA decision in Summer 2026.
NRx aims to offer the first ketamine formulation free of benzethonium chloride, anticipates three years room-temperature stability, has filed patents, and plans U.S. manufacturing to support domestic supply resilience.
NRx Pharmaceuticals (Nasdaq:NRXP) received confirmatory FDA Type C meeting minutes outlining a path to a New Drug Application for NRX-100 (preservative-free ketamine) with a broader proposed indication to treat severe depression, including patients with suicidal ideation.
The FDA confirmed willingness to consider existing adequate and well-controlled trials as Substantial Evidence of Efficacy together with Real World Evidence from Osmind, requested patient-level data, and did not require additional clinical trials. NRx intends to submit an NDA by June 2026.
HOPE Therapeutics (Nasdaq: NRXP) opened a Palm Beach, FL clinic on March 9, 2026, offering one‑day interventional psychiatry treatments for depression and PTSD that combine ketamine and other neuroplastic drugs, transcranial magnetic stimulation (TMS), hyperbaric oxygen, and physician‑led psychotherapy.
Peer‑reviewed publications cited an 87% clinical response rate for a short‑term TMS plus neuroplastic medication protocol; pilot programs with added hyperbaric oxygen reported a 90% return to full function rate. HOPE cites a nationwide partnership with neurocare AG and is now accepting patients by phone.
NRx Pharmaceuticals (Nasdaq: NRXP) appointed Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer effective March 2, 2026. Prof. Brown is a TMS pioneer, Harvard-affiliated clinician-scientist with >$20M in federal funding, and will guide NRx's work combining TMS with neuroplastic medications including NRX-101.
He will collaborate with NRx leadership on development programs and an FDA Investigational New Drug application to test a combined therapy for PTSD and depression in first responders and military personnel.
NRx Pharmaceuticals (Nasdaq: NRXP) completed a Type C meeting with FDA leadership on Feb 17, 2026 and received oral guidance that supports a path to a New Drug Application for NRX-100 (preservative-free ketamine).
The company plans to combine existing adequate, well-controlled trial data with Real World Evidence from >65,000 patients and will seek a broader indication for treatment-resistant depression with suicidality. FDA preliminarily advised no additional nonclinical data or bridging studies would be required. Final meeting minutes and a finalized statistical analysis protocol for the RWE dataset are pending.
NRx Pharmaceuticals (Nasdaq: NRXP) will hold its 2025 annual meeting of stockholders on March 23, 2026 at 10:00 a.m. ET in a virtual-only format at https://www.cstproxy.com/nrxpharma/2026. The Board set a record date of February 12, 2026 for stockholders entitled to notice and to vote. The company said its proxy statement, to be filed with the SEC prior to the meeting, will describe meeting matters and voting procedures.
Because the meeting date is more than 60 days after the prior meeting anniversary, the advance-notice deadline under the bylaws for stockholder proposals and director nominations (other than Rule 14a-8 submissions) is the close of business on January 26, 2026. Submissions must follow the bylaws and be delivered by hand, overnight courier, or certified/registered mail to the company’s principal executive offices.
Bright Mountain Media (OTCQB: BMTM) released an on-demand webinar, “How Connected Research Helped Aruba Reimagine Tourism Marketing,” detailing a sub-30-minute case study of Aruba Tourism Authority, Big Village, and Deep Focus. The campaign shifted messaging to attitudinal segments, linked media activations to CRM, and reportedly delivered record visitation and improved marketing ROI. The campaign won a Gold Magellan Award and Shorty Impact recognition. The company also disclosed CEO Matt Drinkwater purchased 299,500 shares on December 10, 2025 (Form 5 filed).